2026-04-17T05:35:43Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4695172024-11-04T06:09:49Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Zacarías-Fluck, Mariano F author Massó Vallés, Daniel author Giuntini, Fabio author González-Larreategui, Íñigo author Kaur, Jastrinjan author Casacuberta-Serra, Sílvia author Jauset, Toni author Martínez-Martín, Sandra author Martín-Fernández, Génesis author Serrano del Pozo, Erika author Foradada Felip, Laia author Grueso, Judit author Nonell, Lara author Beaulieu, Marie-Eve author Whitfield, Jonathan R. author Soucek, Laura author Universitat Autònoma de Barcelona author 2023 MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease. http://hdl.handle.net/2072/469517 Melanoma MYC Omomyc Signature Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma